Nantkwest Inc (NK) Receives $3.88 Consensus PT from Brokerages

Shares of Nantkwest Inc (NASDAQ:NK) have received an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $3.88.

Several equities analysts have recently weighed in on NK shares. Citigroup downgraded shares of Nantkwest to a “hold” rating and set a $3.00 target price for the company. in a research note on Friday, August 10th. ValuEngine upgraded shares of Nantkwest from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research upgraded shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Wednesday, October 10th. Jefferies Financial Group reiterated a “hold” rating and issued a $3.50 target price on shares of Nantkwest in a research note on Thursday, November 15th. Finally, BidaskClub upgraded shares of Nantkwest from a “sell” rating to a “hold” rating in a research note on Friday, September 28th.

In other news, Director Steve Gorlin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $3.07, for a total value of $153,500.00. Following the completion of the sale, the director now directly owns 224,805 shares in the company, valued at approximately $690,151.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 212,980 shares of company stock valued at $524,037. 72.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in Nantkwest by 40.9% during the 1st quarter. JPMorgan Chase & Co. now owns 46,068 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 13,366 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Nantkwest by 40.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock valued at $521,000 after buying an additional 49,040 shares during the last quarter. Millennium Management LLC raised its holdings in Nantkwest by 402.4% during the 1st quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock valued at $610,000 after buying an additional 125,544 shares during the last quarter. Bridgeway Capital Management Inc. raised its holdings in Nantkwest by 75.0% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock valued at $648,000 after buying an additional 75,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Nantkwest by 144.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock valued at $662,000 after buying an additional 127,694 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

NK stock traded down $0.08 during mid-day trading on Thursday, hitting $2.00. The company had a trading volume of 245,736 shares, compared to its average volume of 1,264,188. The firm has a market cap of $164.79 million, a price-to-earnings ratio of -1.67 and a beta of 3.16. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.31 and a current ratio of 3.31. Nantkwest has a 12 month low of $1.92 and a 12 month high of $5.47.

Nantkwest Company Profile

NantKwest, Inc engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S.

See Also: Initial Public Offering (IPO)

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply